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ABSTRACT
DNA microarray technology provides a promising
approach to the diagnosis and prognosis of tumors
onagenome-widescalebymonitoringtheexpression
levels of thousands of genes simultaneously. One
problem arising from the use of microarray data is
the difficulty to analyze the high-dimensional gene
expressiondata,typicallywiththousandsofvariables
(genes) and much fewer observations (samples),
in which severe collinearity is often observed. This
makes it difficult to apply directly the classical stat-
istical methods to investigate microarray data. In this
paper, total principal component regression (TPCR)
wasproposedtoclassifyhumantumorsbyextracting
the latent variable structure underlying microarray
datafromtheaugmentedsubspaceofbothindepend-
ent variables and dependent variables. One of the
salient features of our method is that it takes into
accountnot onlythe latent variablestructurebut also
the errors in the microarray gene expression profiles
(independent variables). The prediction performance
of TPCR was evaluated by both leave-one-out and
leave-half-outcross-validationusingfourwell-known
microarraydatasets.Thestabilitiesandreliabilitiesof
the classification models were further assessed by
re-randomization and permutation studies. A fast
kernel algorithm was applied to decrease the compu-
tation time dramatically. (MATLAB source code is
available upon request.)
INTRODUCTION
Improvements in cancer classiﬁcation have been of great
importance in cancer treatment. It is difﬁcult to distinguish
tumors, which have similar histopathological appearance
but different clinical course and response to therapy, by the
traditional cancer diagnostic methods that are based primarily
on morphological appearance of tumors (1). DNA microarray
technology provides a powerful approach to the diagnosis and
prognosis of various tumors on a genome-wide scale. By
simultaneously monitoring the expression of thousands of
genes in cells to obtain quantitative information about the
complete transcription proﬁle of cells, microarray technology
makes tailored therapeutics to speciﬁc pathologies possible
(1–4). Despite the usefulness of microarray technology, ana-
lyzingandunderstandingtheobtaineddatahasbeen acomplex
and challenging task. Microarray data analysis methods can be
categorized roughly into unsupervised learning, including
various clustering techniques such as self-organizing map
(5) and hierarchical clustering (6), and supervised learning,
including various classiﬁcation and prediction techniques
(7,8). Some recent applications of supervised learning techni-
ques include molecular classiﬁcation of acute leukemia (1),
classiﬁcation of human cancer cell lines (9), support vector
machine classiﬁcation of cancer tissue samples (10), classify-
ing cancers using artiﬁcial neural networks (11), mapping of
the physiological state of cells and tissues and identiﬁcation of
important genes using Fisher discriminant analysis (12), tumor
classiﬁcation by polychotomous discrimination and quadratic
discriminant analysis after dimension reduction using prin-
cipal component analysis (PCA) or partial least squares (PLS)
(13), PCA disjoint models for cancer classiﬁcation (14), multi-
class tumor classiﬁcation by discriminant PLS and assessment
of classiﬁcation models (15), classiﬁcation by incorporating
PLS within the interactively re-weighed least square steps for
multinomial or binary logistic regression (16) and classiﬁca-
tion using PLS with penalized logistic regression (17).
DNA microarray gene expression data are usually charac-
terized by thousands of variables (genes) with much fewer
observations (samples), resulting in a high degree of multi-
collinearity. This makes it difﬁcult or even impossible to apply
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doi:10.1093/nar/gki144directly classical statistical methods to the analysis of
microarray data. To tackle this kind of collinearity problems,
latent variable methods, such as PCA (18) and PLS (19), have
been developed to reduce the dimensionality of gene expres-
sion data and mitigate the collinearity. These methods assume
that the independent variables (gene expression proﬁles)
are inherently located in a low-dimensional linear subspace,
i.e. they have an intrinsic latent variable structure. PCA
attempts to ﬁnd a set of orthogonal principal components
(linear combinations of original independent variables) to
account for the maximum variations in independent variables
(18). Since the information about the sample classiﬁcation
provided by dependent variable (class membership) is not
taken into account in the extraction of the principal compo-
nents in PCA, the performance of PCA in classiﬁcation or
prediction may not be satisfactory. And this is one of the
reasons why PLS was developed several decades ago to pro-
vide a better performance in calibration and prediction than
PCA (19). In addition, it is well-known that microarray experi-
ments are inﬂuenced by many potential sources of variation/
error and these kinds of variability can be roughly classiﬁed
into three categories: biological variation (genetic or environ-
mental factors, pooled or non-pool), technical variation (dur-
ing extraction, labeling and hybridization) and measurement
error(signaldetection,etc.)(20–22).Thesekindsofvariability
have been analyzed using the ANOVA model to determine the
sources and magnitudes of error/variation in gene expression
proﬁles (22–25). However, in classiﬁcation or prediction using
microarray data, most of the statistical methods (e.g. PCA
and PLS) relating the gene expression proﬁles, X-independent
variables, to other information of interest, Y-dependent vari-
ables (e.g. tumor type or survival time), do not account for
errors in the independent variables, which is one of the import-
ant characteristics of measured data. To tackle these problems
mentioned above, a novel method, total principal component
regression (TPCR), is proposed to not only incorporate the
information of the dependent variables into the construction
of latent structure but also take into account the errors in
both independent variables and dependent variables. A salient
feature of TPCR is that it extracts the latent structure from
the augmented subspace of both independent and dependent
variables, using a weighted least square ﬁtting. This enables
the proposed method to construct latent variables approxim-
ating optimally the actual latent structure and eliminate the
collinearity to a certain degree.
METHODS
Total principal component regression
The basic goal of various projection or dimension-reduction
approaches, for example PCA (18) and PLS (19), is to project
the observations (samples) from the high-dimensional vari-
ables (genes) space to a low-dimensional subspace spanned
by several linear combinations of the original variables, in
order to satisfy a certain criterion. PCA attempts to ﬁnd a set
of orthogonal principal components to explain as much vari-
ance as possible in independent variables (X). The perform-
ance of PCA in classiﬁcation may not be satisfactory from
the predictive point of view, because there is no guarantee that
the principal component representing the large variance in
X should necessarily be the component strongly related to
dependent variables (Y). To solve this problem, the informa-
tion of dependent variables should be taken into account
during the construction of orthogonal components. One way
to do so is to maximize the sample covariance between the
linear combination of dependent variables and the orthogonal
component of independent variables, which is the essence of
PLS (15,26,27), as shown by the objective criterion of PLS:
w,c fg = argmax
wTw¼1
cTc¼1
cov2 Xw,Yc ðÞ 1
where w and c denote the weight vectors of X and Y, respect-
ively. It has been proved that w and c are related to the
following eigenvalue problems (26,27):
XTYYTXw = aw
YTXXTYc = ac 2
where a is the maximum eigenvalue and the weight vectors w
and c can thus be calculated as the ﬁrst left and right singular
vector of X
TY, respectively.
Another simple way to make use of the information of
dependent variable would be to construct the orthogonal com-
ponents, rather than only from the subspace of X, from the
augmented subspace of both X and Y, that is, ﬁnding a low-
dimensional subspace to best ﬁt the subspace spanned by both
X and Y, which is one of the motivations of TPCR.
In classical regression/prediction models, the independent
variables are usually assumed to be non-stochastic, in other
words, there is no error in the independent variables or at least
the error is negligible. However, it is well-known that various
variation/error may be introduced during a multi-step micro-
array experiment and these kinds of variation/error are usually
not negligible. In order to account for errors in both independ-
ent variables and dependent variables, the error-in-variables
(EIV) model (28–32) was used in this paper:
Y = e Y Y + EY 3
X = e X X + EX 4
e Y Y = e X XB 5
where e X X and e Y Y denote the systematic or unobservable true
valuesforindependentvariablesXN·Panddependentvariables
YN·M,respectively;EX,EYrepresenttherandomerrormatrices
whose rows are assumed to be independently, identically dis-
tributed (i.i.d) with common mean vector 0 and common cov-
ariancematricess
2
XIPands
2
YIM(IPandIMdenoteappropriate
identitymatrices),respectively;BisaP·Mmatrix.Equation5
impliesanassumptionoftheEIVmodel,i.e.thereexistsalinear
functionalrelationshipbetweenthesystematicortruevaluesof
X and Y (29,30,32). In the case of microarray data analysis, in
our opinion, the errors in the independent variables (gene
expressionproﬁles) mayinclude the randomﬂuctuations intro-
duced by microarray technology itself, including measurement
error and/or technical variation, while the biological variation
(the true difference in gene expression) is embedded in the
systematic part of independent variables.
Suppose the systematic or true values of the independent
variables under observation is actually driven by a set of unob-
servable latent variables, i.e. they lie in a lower dimensional
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deﬁne a column-wise orthonormal matrix TN·K (K < P and
T
TT = I, where superscript T denotes the transpose of a
matrix), whose columns provide the basis for the subspace
of both e X X and e Y Y:
e X X = TG 6
e Y Y = e X XB = TGB = TF 7
where GK·P and FK·M are the corresponding loading mat-
rices for e X X and e Y Y, respectively. T can be seen as the common
latentstructureforboth e X Xand e Y Y.OnsubstitutionofEquations6
and 7 into the previous EIV model, we obtain the EIV latent
variable model (33–35):
Y = TF + EY 8
X = TG + EX 9
The assumption behind this model is that there is a linear
functional or structural relationship between the systematic
or true part of X and Y and this relationship can be linked
bya set of unobservable underlying latent variables T (33–35).
Note that just like the assumption of ordinary least squares is
not strictly complied with in practical applications, although
the i.i.d. assumption about the error structure in the TPCR
model may not be rigorously valid in some cases, it should
not degrade the performance of this model too much if the
violation isnottoosevere. Itisworthy topointoutthatamodel
taking into account the error information in the independent
variable, even if incomplete, would provide more insight into
the realistic characteristics and structure of data and better
performance than those incorporating no such information.
Andtheviolationofthisassumptionmaybecorrected partially
by some preprocessing techniques such as transformation and
scaling.
A criterion for solving this EIV latent variable model is:
min
T,G,F
TTT¼I
kX   TGk
2
F
s2
X
+
kY   TFk
2
F
s2
Y
 !
10
where kMkF denotes the Frobenius norm of a matrix, that is,
kMkF = [tr(MM
T)]
1/2.
To deal with the error in both independent variables and
dependent variables, let meta parameter l (>0) be:
l
2 =
s2
X
s2
Y
11
Then Equation 10 can be rewritten as
min
T,G,F
TTT¼I
kX   TGk
2
F +l
2kY   TFk
2
F
  
12
¼ min
T
min
G
kX   TGk
2
F +l
2min
F
kY   TFk
2
F
  
13
Noting that TT
T is the projection matrix, it is easy to see
from least square analysis (36–38) that:
kX   TGk
2
F > kX   TTTXk
2
F 14
kY   TFk
2
F > kY   TTTYk
2
F 15
Thus, Equation 13 is equivalent to
min
T
kX   TTTXk
2
F +l
2kY   TTTYk
2
F
  
16
¼ min
T
k X   TTTX,lY   lTTTY
  
k
2
F 17
¼ min
T
kA   TTTAk
2
F 18
¼ min
T
k I   TTT   
Ak
2
F 19
where A is the N · (P + M) augmented matrix of X and Y, that
is, A = (X, lY).
Noting that (I TT
T) stands for the N · N projection matrix,
which projects on the orthogonal complement of the subspace
spanned by T, Equation 19 can be minimized when T is the
ﬁrst Klargest principal component forthe augmented matrix A
(18). Let the singular value decomposition (SVD) of A be
A = U VT 20
where left singular vectors U = (u1, ...,uN) 2 R
N·N with
U
TU = IN; right singular vectors V = (v1,..., v(P+M)) 2
R
(P+M)·(P+M) with V
TV = I(P+M),   is a diagonal matrix con-
taining singular values. Then let T be the ﬁrst K columns of U:
T = u1,...,uK ðÞ 21
Thus the estimates of e X X and e Y Y can be obtained by:
^ X X = TTTX2 2
^ Y Y = TTTY2 3
The regression coefﬁcients estimated using TPCR are
given by
BTPCR = TTX
   þ
TTY2 4
wheresuperscript+denotesthegeneralizedinverseofamatrix.
Fast kernel EVD algorithm for wide data
The speed and time of calculations have always been the
practical and important problems in the implementation of
algorithm or method in multivariate data analysis. Microarray
dataset typically consists of thousands of variables and less
than100samples(P   N).Forsuch‘wide’data(39),thecom-
putation time needed for matrix decomposition using classical
SVD algorithm (e.g. in MATLAB: [U, S, V] = svd (A), where
svd is the build-in function to calculate the singular vectors,
U and V, and singular values S) may be pretty long. The
situation becomes even worse when cross-validation isapplied
to evaluate the methods, which is the typical case in tumor
classiﬁcation. Therefore, an efﬁcient and fast algorithm is
needed to calculate the singular vectors from microarray data.
Since the kernel matrix AA
T contains the same information
(e.g. eigenvalues) as the covariance matrix A
TA while the size
of AAT (N · N) is much smaller than that of AN·(P+M) and
(A
TA)(P+M)·(P+M) (P   N), it would be much faster to cal-
culate the left singular vectors or eigenvectors U from
(AA
T)(N·N) by eigenvalue decomposition (EVD) than from
AN·(P+M) by SVD (39).
58 Nucleic Acids Research, 2005, Vol. 33, No. 1Thus, the modiﬁed fast kernel EVD algorithm to calculate
T is:
U,S
2 hi
= eig AAT   
25
T = u1, ...,uK ðÞ ; the first K columns of U2 6
where eig is the build-in function of MATLAB to calculate
eigenvectors and eigenvalues of a matrix, U denotes the eigen-
vectorsofAA
TorthesingularvectorsofAandS
2isadiagonal
matrix containing eigenvalues of AA
T (S contains the singular
values of A).
TPCR for discrimination
When TPCR is used for classiﬁcation, the matrix of dependent
variables(Y)containstheinformationabouttheclassmember-
ships, with element yik = 0o r1( i = 1, ..., N; k = 1, ..., M;
where N and M is the number of samples and the number
of tumor classes, respectively). If the i-th sample belongs to
class k, then yik = 1, otherwise yik = 0.
The prediction of dependent variables on a new set of
samples is made by:
Ynew = XnewBTPCR 27
where Xnew is the gene expression proﬁles for the new set of
samples, and Ynew is the predicted values for these samples.
The identity of the class membership of each new sample
(each row in Ynew) is assigned as the column index of the
element with the largest predicted value in this row.
Meta parameter l
As stated above, the relative magnitude of errors in the
independent variables and dependent variables is given by
meta parameter l in TPCR model. It is important to choose
the appropriate l to obtain the best prediction performance.
Considering two extreme cases for l (>0):
(i) If l=0, i.e. s2
x = 0, which means no error is considered
in X matrix, then the augmented matrix A = (X, lY) = X;
therefore, T will be the principal components of X itself.
In other words, the TPCR model degenerates to the clas-
sical principal component regression (PCR) model in
this extreme case. Note that no information about Y is
taken into account in the construction of latent variable
in this case.
(ii) If l is very large, the variation of the columns of lY
would be much larger than that of the columns of X in
the augmented matrix A. In this case, the major principal
components T will come largely from lY, since the
PCA always projects to the directions showing the largest
variation. Therefore, the prediction performance of T for
the new sample Xnew will be poor.
The choice of l depends on the experience about the data and
the computation power available. In practice, the optimal meta
parameter l (>0) is chosen from an appropriate set according
to leave-one-out cross-validation (LOOCV) procedure.
Gene selection
Variable (gene) selection is important for the successful
analysis of gene expression data since most of the genes do
not provide useful information for classiﬁcation, and including
all of them in the modeling process will degrade the perform-
ance ofthe model. Therefore, non-informative genes should be
removed before building a classiﬁcation model. There exist
different approaches for gene selection such as neighborhood
analysis (1), signiﬁcance analysis of microarrays (40), Wilks’
lambda (12), t-score and critical score (13,41) and classiﬁer
feedback approach (14).
In this paper, the sum of squared correlation coefﬁcients
between gene expression and each of the dependent variables
is used to select the genes for analysis (15). For example, the
g* = 100 genes are taken as the ﬁrst 100 genes with the largest
values of sum of squared correlation coefﬁcients.
Assessment of prediction method by leave-one-out
and leave-half-out CV
LOOCV has become a standard procedure to evaluate the
performance of various classiﬁcation methods in microarray
data analysis. Note that when gene selection or dimension
reduction is used together with LOOCV procedure, a common
mistake made in tumor classiﬁcation using microarray gene
expression proﬁles, was to perform gene selection or dimen-
sion reduction before CV loop. However, such incomplete
LOOCV procedure is well known to be substantially biased
and prone to generating spuriously good results since the
information about all the samples is used for gene selection
or dimension reduction before the CV loop (15,42–44). In
this paper, the complete LOOCV (the gene selection and
dimension reduction within the CV loop) was applied.
LOOCV is nearly unbiased, but often with unacceptably
high variability, especially for dataset with small number of
samples (45–48), implying that it may give unreliable good
prediction results due to the effect of high variance/variability,
especially when the number of samples is small (just like
ordinaryleastsquaremaygiveunreliableresultduetothelarge
variance if there exists severe collinearity in the data, even if it
is unbiased). External validation can provide some protection
against over-ﬁtting caused by LOOCV, but there may not be
enough samples for external test, especially for microarray
data analysis (due to the relatively expensive cost, etc.). In
this case, a re-randomization study, leave-half-out cross-
validation(LHOCV), providesanalternativeapproachtoeval-
uate the prediction method more realistically (14,15,41,48).
Brieﬂy, the whole datasets, including original training and test
dataset, are pooled together and split randomly (half/half) into
a new training dataset and a new test dataset; the randomly
generated training dataset is used to derive a classiﬁcation
model(selectgenes,reducedimensionandcalculateregression
coefﬁcients) that is then applied to classify the corresponding
new testdataset. This LHOCVprocedure isrepeated 100times
(splitting the pooled dataset randomly for 100 times) to avoid
chance factor.
RESULTS AND DISCUSSION
Acute leukemia data
Thewell-knownleukemiadatasetwasmeasuredbyGolubetal.
(1) using Affymetrix high-density oligonucleotide microarray
containing probes for 6817 human genes and has become a
benchmark for the evaluation of various cancer classiﬁcation
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marrow samples from acute leukemia patients, including 19
B-cell acute lymphoblastic leukemia (B-ALL), 8 T-cell acute
lymphoblastic leukemia (T-ALL) and 11 acute myeloid
leukemia (AML). The original independent (test) dataset
consisted of 24 bone marrow and 10 peripheral blood samples
(19 B-All, 1 T-ALL and 14 AML). The gene expression data
was log transformed and centered to have mean zeros across
samples during the cross-validation process.
The original 38 training samples and 34 test samples were
pooled together and then classiﬁed by TPCR using LOOCV
with g* = 50, 100, 200, 500 and 1000 genes selected (l was
takenfrom the values: 0, 0.001,0.01, 0.1, 1–20 with intervalof
1,40–100withintervalof20,200,1000,10000and100000in
this paper) and the results are shown in Table 1. One ALL
sample (#17; error rate 1.39%; l=19) was misclassiﬁed by
TPCR. In our previous study (15), discriminant PLS (D-PLS)
was used to classify the same dataset using the same gene
selection method and resulted in at least 2 (2.78%) misclassi-
ﬁcations.Thisdatasetwasalsoanalyzed byNguyenandRocke
(13) using polychotomous discrimination and quadratic dis-
criminant analysis together with dimension reduction by PCA
or PLS and at least 8 (11.1%) and 3 (4.2%) samples were
misclassiﬁed using PCA and PLS for dimension reduction,
respectively (from A2 procedure; note that both A0 and A1
procedures are incomplete LOOCV and should not have been
used to compare with our results).
Hereditary breast cancer data
The gene expression proﬁles of primary breast tumor samples
from seven carriers of the BRCA1 mutation, eight carriers of
the BRCA2 mutation and seven patients with sporadic cases of
breastcancerweremonitoredwithamicroarrayof6512cDNA
clones of 5361 genes and a total of 3226 genes were selected
for analysis (49). The gene expression data were centered
to have mean zeros across samples during cross-validation
process.
Classiﬁcation results based on TPCR using LOOCV are
presented in Table 2 and at the best, four samples were mis-
classiﬁed (error rate 18.18%, l=9), which is better than the
best result (22.7%, 5 misclassiﬁcation) of D-PLS (15) and the
result (5 misclassiﬁcations) obtained by Hedenfalk et al. (49).
In the study of Nguyen and Rocke (13), at least six (27.3%)
misclassiﬁcations were found using A2 procedure. The per-
centage of misclassiﬁed samples by TPCR and other methods
was pretty high, implying the difﬁculty to accurately classify
these 22 tumor samples based on gene expression proﬁles.
This may be due to the inherent lack of discriminating power
of the dataset (e.g. the small sample size, diagnosis error or the
lack of differentiating power for the expression proﬁles of
3226 genes to separate these 22 samples) (15,49). Another
possibility could be that the underlying structure of the data
(e.g. inner non-linear relationship) was not characterized by
the methods used (15). As pointed out before by Hedenfalk
et al. (49), ‘the use of microarray covering a larger proportion
ofthe genomeandtheanalysisoflargernumbersoftumormay
makepossibleamoreprecise molecularclassiﬁcation ofbreast
cancer’.
Small, round blue cell tumor data
The small, round blue cell tumors (SRBCTs) of childhood,
including neuroblastoma (NB), rhabdomyosarcoma (RMS),
non-Hodgkin lymphoma (NHL) and the Ewing family of
tumors (EWS), are difﬁcult to distinguish due to their similar
appearances in routine histology. Khan et al. (11) monitored
the gene expression proﬁles of 6567 genes for these four types
of malignancies using cDNA microarrays and reduced the
number of genes to 2308 by quality ﬁltering for a minimal
level of expression. The original 63 training samples included
both tumor biopsy materials (13 EWS and 10 RMS) and cell
lines (10 EWS, 10 RMS, 12 NB and 8 Burkitt Lymphomas
(BL, a subset of NHL). The original test samples contained
both tumors (5 EWS, 5 RMS and 4 NB) and cell lines (1 EWS,
2 NB and 3 BL). This dataset was centered to have mean zeros
across samples for analysis.
The pooled-together 83 samples were classiﬁed by TPCR
using LOOCV with g* = 50, 100, 200, 500 and 1000 genes
selected and the results are presented in Table 3. All the
sampleswere correctly classiﬁedusing 3–6TPCRcomponents
with g* = 100, 200 and 500 genes selected (l=200), indic-
ating a good prediction performance of TPCR on this dataset.
The same result (0 misclassiﬁcation) was also obtained in
other studies (15,50–53), indicating good class separability
of this dataset. Khan et al. (11) also found 0 misclassiﬁcation
using artiﬁcial neural networks for 88 samples, including
5 non-SRBCT samples. However, the dimension reduction by
Table 1. Classification results for leukemia dataset
g* Number of TPCR components (%, l=19, LOOCV)
1 23456
50 13.89 2.78 4.17 5.56 8.33 6.94
100 15.28 4.17 4.17 5.56 5.56 5.56
200 13.89 2.78 2.78 1.39 4.17 4.17
500 13.89 2.78 2.78 4.17 4.17 4.17
1000 15.28 2.78 4.17 4.17 4.17 4.17
Givenarethepercentagesofmisclassificationoutof72samplesusingLOOCV.
Table 2. Classification results for hereditary breast cancer dataset
g* Number of TPCR components (%, l=9, LOOCV)
123456
50 54.55 45.45 40.91 40.91 45.45 40.91
100 59.09 50.00 40.91 31.82 36.36 22.73
200 54.55 22.73 18.18 27.27 31.82 31.82
500 77.27 31.82 27.27 36.36 40.91 40.91
1000 59.09 63.64 45.45 45.45 40.91 40.91
Givenarethepercentagesofmisclassificationoutof22samplesusingLOOCV.
Table 3. Classification results for SRBCT dataset
g* Number of TPCR components (%, l=200, LOOCV)
123 4 5 6
50 36.14 14.46 1.20 0.00 0.00 0.00
100 34.94 14.46 0.00 0.00 0.00 0.00
200 34.94 14.46 0.00 0.00 0.00 0.00
500 34.94 15.66 0.00 0.00 0.00 0.00
1000 34.94 18.07 1.20 0.00 0.00 0.00
Givenarethepercentagesofmisclassificationoutof83samplesusingLOOCV.
60 Nucleic Acids Research, 2005, Vol. 33, No. 1PCA was performed using all the 88 samples before the
validation procedure, which may suffer from bias.
NCI60 data
Using cDNA microarrays containing 9703 cDNA clones
representing  8000 unique genes, Ross et al. (9) and Scherf
et al. (54) studied gene expression in the 60 human cancer cell
lines used in the NCI anticancer drug screening program. The
60 human cell lines were derived from tumors from a variety
of tissues and organs, which, in contrast to clinical tumors,
have been characterized pharmacologically by treatment with
>70000 different agents, one at a time and independently (54).
As in the study of Nguyen and Rocke (13), ﬁve cancer types
were used for multi-class classiﬁcation: eight melanoma,
eight renal, six leukemia, seven colon and six CNS. A subset
of 1376 genes selectively ﬁltered from initial 9703 genes and
40 molecular characteristics (targets) individually assessed by
various laboratories was used to discriminate the different
types of cancers (54). Since there are some missing gene
expression values in this dataset, genes with <2 missing values
were used for classiﬁcation through replacing the missing
values (1 or 2) with the median of the gene expression (13).
This resulted in a gene expression dataset with 35 samples and
1299 genes. This dataset was centered to have mean zeros
across samples in analysis. TPCR was then applied to this
dataset with g* = 50, 100, 200, 500 and 1000 genes selected.
The misclassiﬁcation results using TPCR are given in
Table 4. The best result was one misclassiﬁed sample (#15
ME:LOXIMVI, 2.86%, l=20), the same as the best result
using D-PLS (15), while the best result obtained by Nguyen
and Rocke (13) was 2 (5.7%) and 3 (8.6%) misclassiﬁcations
using PCA and PLS for dimension reduction, respectively
(A2 procedure). The classiﬁcation performance of TPCR on
this dataset is good, given the small sample-to-class ratio
(35 samples and 5 classes). It would be worthy to note that
ME:LOXIMVI, although supposedly a melanoma in origin,
was reported to lack melanin and other useful marker for the
identiﬁcation of melanoma cells (55) and showed different
characteristic pattern from the other seven melanoma lines
(9,54). Furthermore, in an earlier study involving the cluster-
ing of the 60 cancer cell lines based purely on their sensitivity
to tens of thousands of potential anticancer compounds,
ME:LOXIMVI was also found to be different from other
melanoma cell lines; instead, it was found to be more similar
to a group of colon cancer cell lines (56).
Evaluation of TPCR more realistically by LHOCV
As demonstrated in the above LOOCV studies with four well-
publicizedmicroarray datasets, TPCR showed better or atleast
comparable prediction performance compared with other
publishedmethods.However,LOOCVmayprovideunreliable
Table 4. Classification results for NCI60 dataset
g* Number of TPCR components (%, l=20, LOOCV)
1 234 5 6
50 100.00 60.00 60.00 8.57 8.57 8.57
100 91.43 57.14 37.14 2.86 5.71 5.71
200 77.14 57.14 20.00 2.86 2.86 5.71
500 77.14 57.14 20.00 2.86 5.71 5.71
1000 77.14 48.57 20.00 2.86 2.86 2.86
Givenarethepercentagesofmisclassificationoutof35samplesusingLOOCV.
Table 5. Classification results using TPCR and PLS under LHOCV procedure for Leukemia, hereditary breast cancer, SRBCT and NCI60 datasets
g* Number of TPCR components Number of PLS components
123456123456
Leukemia dataset (%, LHOCV) (l=19)
50 14.97 4.19 5.83 6.72 6.61 6.50 15.00 4.53 5.28 5.19 5.36 6.08
100 15.08 4.08 4.61 5.00 5.31 5.19 15.22 4.17 4.36 4.50 4.75 5.14
200 15.19 3.89 3.75 3.92 4.89 4.97 15.28 4.03 4.36 4.53 4.56 4.89
500 14.86 4.31 4.28 4.06 4.14 4.25 14.94 4.36 4.75 4.67 4.58 4.58
1000 14.72 5.25 4.83 4.44 4.19 4.19 14.72 4.72 4.89 4.61 4.61 4.72
Hereditary breast cancer dataset (%, LHOCV) (l=9)
50 60.27 47.18 47.00 46.09 45.55 46.27 60.27 47.91 47.09 46.27 46.55 46.45
100 58.91 45.09 45.00 45.81 44.18 43.82 58.55 44.55 45.36 44.45 44.36 44.18
200 58.73 45.45 45.27 44.64 44.00 44.18 59.18 46.09 44.55 44.00 44.00 44.91
500 61.09 46.45 46.00 45.27 44.18 44.73 60.64 45.73 45.00 44.45 45.18 45.27
1000 64.64 54.73 49.00 48.27 47.55 46.45 63.55 50.91 48.91 47.73 47.45 47.45
SRBCT dataset (%, LHOCV) (l=200)
50 40.85 18.63 0.83 0.39 0.56 0.59 45.07 20.98 0.73 0.54 0.56 0.68
100 41.29 18.80 0.66 0.17 0.29 0.22 46.54 21.66 0.61 0.22 0.39 0.37
200 42.59 19.22 1.07 0.32 0.27 0.32 49.66 21.54 0.90 0.29 0.39 0.39
500 43.83 20.71 2.20 0.78 0.56 0.51 52.71 23.63 1.88 0.66 0.56 0.63
1000 45.61 22.95 4.54 1.85 1.15 0.80 54.88 26.22 4.07 1.37 0.71 0.61
NCI60 dataset (%, LHOCV) (l=20)
50 72.65 55.24 36.12 13.18 13.41 13.88 71.00 53.12 34.47 14.18 13.88 14.53
100 72.18 54.00 34.41 11.12 11.35 11.41 70.24 52.29 32.82 11.47 11.65 11.41
200 70.94 52.59 33.18 9.47 9.82 10.12 70.47 51.41 30.82 9.65 10.65 10.65
500 70.59 50.94 31.35 8.82 9.24 9.53 70.65 50.47 30.71 9.06 9.53 9.76
1000 70.76 49.29 30.35 9.53 9.00 9.41 71.35 49.82 30.88 9.00 9.82 9.71
Givenarethepercentagesofmisclassificationsaveragedover100re-randomizations.(Boldnumberdenotestheminimumvalueinthesamerow;boldandunderlined
number means the minimum value in the whole 5 · 6 data matrix).
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assess the prediction performance of TPCR more realistically,
TPCR was further compared using LHOCV procedure
with the well-known PLS method, which has been widely
used in microarray analysis (13,15–17,41,57–60), including
tumor classiﬁcation. This LHOCV procedure was repeated
100 times and the average misclassiﬁcation error rates over
100 re-randomizations for the four microarray datasets are
shown in Table 5.
It is obvious that the error rates using LHOCV were higher
than those using LOOCV since the size of the dataset is small
and only half of the total samples were used to construct the
classiﬁcation model under LHOCV procedure. On the other
hand, it can be observed that the minimum LHOCV error rate
obtained by TPCR is consistently lower than that obtained by
PLS for each of the four microarray datasets. Actually, with
the same number of genes selected, the minimum LHOCV
error rate by TPCR (bold number in Table 5) is, in most
cases, lower than that by PLS, indicating that the prediction
performance of TPCR is better than or at least comparable to
the well-known PLS method.
Assessment of the reliability of classification models
by permutation analysis
Giventherelativelysmallsamplesizeofmicroarraydatasetsin
cancer classiﬁcation, especially for hereditary breast cancer
dataset and NCI60 dataset, it is important to evaluate the
stability and reliability of a classiﬁcation model. There are
various statistical methods to assess the reliability when there
arenotenoughsamplesavailabletoperformexternalvalidation
(13–15,41).Inthispaper,so-calledpermutationorshufﬂestud-
ies were performed to compare the misclassiﬁcation error rates
using TPCR with those expected at random. Initially, the class
memberships of all the samples were permuted (the rows of
Y matrix were shufﬂed) while keeping the gene expression
proﬁles (X matrix) unchanged; then the newly generated
randomdatasetwithshufﬂedYandunchangedXwasanalyzed
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Figure 1. Distributionoferror rate(percentageof misclassified samples)over 100 runsof permutation analysis(the originalclass memberships ofall sampleswere
randomlyshuffledfor100timesandthenusedtogetherwithoriginalgeneexpressionprofilesforclassificationbyTPCRusingthesameLOOCVasappliedbeforefor
original dataset). The solid line with asterisk labeled in each plot represents the minimum error rate using LOOCV for each original dataset: (a) Leukemia dataset
(number of selected genes, TPCR component number, l and corresponding LOOCV error rate for the original dataset: 200, 4, 19 and 1.39%); (b) Hereditary breast
cancer dataset (200, 3, 9 and 18.18%); (c) SRBCT (50, 4, 200 and 0.00%); and (d) NCI60 (100, 4, 20 and 2.86%).
62 Nucleic Acids Research, 2005, Vol. 33, No. 1byTPCR usingexactlythe sameLOOCVprocedure asapplied
before to the original dataset (gene number, TPCR component
numberandmetaparameterlwerethesameasthosechosento
obtaintheminimumerrorratesfororiginaldatasets,asshownin
Tables 1–4). This procedure was carried out 100 times and the
distributions of the error rates over 100 permutations for the
four datasets are plotted in Figure 1 and compared with
the minimum misclassiﬁcation error rates obtained from
original datasets. It is obvious that, in all cases, the estimated
errorrateobtainedbyTPCRfororiginaldatasetissigniﬁcantly
lower than what would be expected at random. This kind of
permutation analysis can be used to test whether a complete
cross-validation is performed as well as whether there is some
real structure or classiﬁcation information inside the dataset. If
an incomplete LOOCV is applied or a dataset with no classi-
ﬁcation information (e.g. random dataset) is analyzed, the esti-
mated error rate obtained from original dataset will be close to
that calculated from the shufﬂed dataset.
Another randomization analysis applied to further assess the
stability and reliability of a classiﬁcation model is to examine
the distribution of the error rates over 100 re-randomizations
obtained using LHOCV (14,15), especially when there is
inadequate sets of data. If the classiﬁcation model is unstable
during the 100 re-randomization or perturbations introduced
by this procedure, the estimate of the predictive ability is un-
likely to be reliable (46). The distribution plots of misclassi-
ﬁcation error rates over 100 re-randomizations using LHOCV
for the four microarray datasets are shown in Figure 2 (genes,
the number of TPCR components and meta parameter l were
chosen according to the minimum averaged LHOCV error rate
for each dataset). Substantial stability of the classiﬁcation
models can be observed on both Leukemia (Figure 2a) and
SRBCT (Figure 2c)datasets with small averaged error rate and
variance, while the classiﬁcation model on hereditary breast
cancer dataset (Figure 2b) is unstable with relatively large
averaged error rate and variance, possibly due to the small
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Figure2.Distributionoferrorrate(percentageofmisclassifiedtestsamples)over100runsofLHOCVorre-randomizationanalysisusingTPCR(theoriginaldataset
wasrandomlysplit,half/half,intotrainingandtestsamplesfor100times,thenthenewgeneratedtrainingdatasetwasusedtopredictthetestdatasetusingTPCR):(a)
Leukemiadataset(numberofselectedgenes,numberofTPCRcomponents,landcorrespondingaveragedLHOCVerrorrate:200,3,19and3.75%);(b)Hereditary
breast cancer dataset (100, 6, 9 and 43.82%); (c) SRBCT (100, 4, 200 and 0.17%); and (d) NCI60 (500, 4, 20 and 8.82%).
Nucleic Acids Research, 2005, Vol. 33, No. 1 63sample size or inherent difﬁculty to discriminate the tumors.
Taken together, the reliability of the four classiﬁcation models
is in the decreasing order: SRBCT > Leukemia > NCI60 >
Hereditarybreastcancer,thesameorderasobtainedpreviously
using PLS (15).
Comparison of the speed of classic SVD algorithm
and fast kernel EVD algorithm
The classic SVD algorithm ([U, S, V] = svd (X), build-in
function in MATLAB) and a fast kernel EVD algorithm ori-
ginated from the work of Wu et al. (39), [U,  
2] = eig (XX
T),
were compared in terms of the time used to calculate the left
singular vectors U from the four microarray gene expression
proﬁles (X matrix), and the results are shown in Table 6 (Intel
Pentium 4 1.70 GHz CPU; 512 MB RAM; Window 2000 Pro;
MATLAB R14). It is clear that the fast kernel EVD algorithm
is much faster than the SVD algorithm, with a speed increase
ranging from 147 (NCI60) to 696 times (Leukemia).Generally
speaking, the improvement of the speed increases asthe sizeof
the dataset increases. Considering that the time-consuming
cross-validation procedure was applied to select optimal
meta parameter l and to evaluate the method, the improve-
ment of speed is very signiﬁcant, especially for LHOCV in
which 100 runs of re-randomizations were performed.
CONCLUSIONS
In this paper, based on the EIV model, we proposed a novel
method called TPCR to perform multi-class classiﬁcation of
tumor samples by taking into account the errors in microarray
gene expression proﬁles. In addition, the latent variable struc-
tureunderlyingthemicroarraydatawasalsotakenintoaccount
in ourmethod tomitigate the collinearity thatresultedfrom the
high-dimensional microarray data, which shows a salient
advantage of our method over the classical EIV model. Four
well-known microarray datasets were used to demonstrate that
the performance of TPCR is better than or at least comparable
to other published methods in the classiﬁcation of tumors.
A major advantage of TPCR over other methods is that it
takes into account not only the errors in both independent
variables and dependent variables but also the latent structure
from the augmented subspace of independent and dependent
variables.AfastkernelEVDalgorithmwasappliedtodecrease
dramatically the time needed to extract the latent variables.
The reported error rates of classiﬁcation model using TPCR
from the original datasets were shown to be signiﬁcantly lower
than what would be expected by chance from shufﬂing or
permuting the memberships of samples. By half-half
randomly splitting the original dataset into training and test
samples for 100 times, the stability and reliability of the
classiﬁcation models were assessed by the distributions of
the error rates over 100 re-randomizations and were shown in
thedecreasingorder:SRBCT>Leukemia>NCI60>Hereditary
breast cancer.
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